ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)

9 Months Ended

Sep. 30, 2021

Supplemental cash flow information for the nine months ended September 30, 2021 and 2020 is as follows:

	2021		2020
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	8,346,968	$	7,303,753
Non-cash Financing and Investing Activities:
Equipment acquired reflected in accounts payable and accrued liabilities	$	1,382,818	$	1,468,147
Right-to-use assets in exchange for lease obligations	$	2,844,875	$	1,738,156